The investigational compound, MIM-D3, is currently in Phase 2 development. It has been developed by Mimetogen Pharmaceuticals and could potentially be a new class of agents called TrkA agonists.
Dry eye therapies on the market increase tear production without addressing tear quality. MIM-D3 stimulates mucin production, which removes allergens, pathogens and debris in addition to lubricating the eye.
More Articles on Ophthalmology:
University of Oklahoma’s Dean McGee Eye Institute Receives $110k Grant from Research to Prevent Blindness
Florida Society of Ophthalmology Presents Dr. William Mallon With Leadership Award
Dr. J. Ryan McManus Joins Munson Medical Center Staff
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.